Tiziana Life Sciences announced that a preclinical study of its intranasal foralumab in combination with semaglutide (Ozempic / Wegovy) demonstrated synergistic effects in a mouse model of obesity, improving liver function and reducing inflammation more than semaglutide alone.
The company says that it plans “to advance these promising preclinical findings into further clinical development, with the goal of initiating in-human clinical trials in the future.” The mouse study was conducted at Brigham and Women’s Hospital, which has been conducting human studies of intranasal foralumab in patients with multiple sclerosis and Alzheimer’s disease.
Scientific Advisory Board Chair Howard Weiner, who co-directed the study, commented, “We are excited by the potential of this novel combination. Nasal foralumab’s ability to modulate immune response in humans has always been promising. Now, combining anti-CD3 with semaglutide resulted in additional benefit on liver homeostasis and reduced inflammation in this mouse model. This could pave the way for an entirely new approach in treating obesity-related metabolic disorders.”
Tiziana CEO Ivor Elrifi said, “We are excited by these findings, which demonstrate nasal Foralumab’s potential to significantly enhance the therapeutic effects of semaglutide. This combination may present a breakthrough approach to treating not only obesity but also the downstream metabolic complications that are often hard to manage with current therapies.”
Read the Tiziana Life Sciences press release.
